Sandeep Bajaj, MD
Interventional Cardiology · Winter Park, FLNPI 1447254800
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (59.1%), speaking fees and education — rather than concentrated in one kind of arrangement. 52 manufacturers reported payments, led by Pfizer at 41.9% of the total.
Across 433 payments — averaging $37.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$7K
- Novartis$1K
- Amgen$936
- Bard Peripheral Vascular, Inc.$835
- E.r. Squibb & Sons, L.L.C.$514
- Cvrx, Inc.$376
- plus $5K from 46 others
Across 10 payments — averaging $23,833 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$230K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$9K
What the payments were for
- Speaking & faculty fees$4,00025%
- Food & beverage$9,50159%
- Education$2,56516%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ELIQUIS$6,500
- Repatha$350
- OPTIMIZER$259
- VENOVO$159
- Barostim Neo System$155
- Cleerly Ischemia$153
- Cleerly Labs$153
- FFRct$152
- Zero Gravity$147
- Edora 8 DR-T$147
- BioMonitor$147
- Acticor 7 VR-T DX$147
- Micra$127
- LOKELMA$125
- ENTRESTO$122
- Epclusa$121
- Rotarex$120
How this compares
$16,066 in reported general payments places this provider in the 70th percentile of 623 interventional cardiology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 507 | $513,881 |
| EntrestoSacubitril/Valsartan | 209 | $230,905 |
| CamzyosMavacamten | 27 | $197,410 |
| XareltoRivaroxaban | 173 | $148,553 |
| Repatha SureclickEvolocumab | 99 | $88,108 |
| BrilintaTicagrelor | 76 | $72,027 |
| MultaqDronedarone Hcl | 32 | $41,334 |
| JardianceEmpagliflozin | 41 | $36,983 |
| MounjaroTirzepatide | 34 | $35,792 |
| FarxigaDapagliflozin Propanediol | 20 | $18,661 |
| VerquvoVericiguat | 11 | $17,387 |
| Metoprolol Succinate | 798 | $12,527 |
| VascepaIcosapent Ethyl | 21 | $11,166 |
| LivaloPitavastatin Calcium | 17 | $10,599 |
| Isosorbide Dinitrate | 183 | $9,996 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $6,729 | $513,881507 claims |
| NovartisEntresto | $1,371 | $230,905209 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $514 | $197,41027 claims |
| Johnson & JohnsonXarelto | $258 | $148,553173 claims |
| AstraZenecaBrilinta, Farxiga | $142 | $90,68796 claims |
| Sanofi-aventis U.S. LLCMultaq | $187 | $41,33432 claims |
| Boehringer IngelheimJardiance | $257 | $36,98341 claims |
| MerckVerquvo | $288 | $17,38711 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $77 | $10,59917 claims |
| Esperion Therapeutics, Inc.Nexlizet | $345 | $9,26515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 623 interventional cardiology providers in Florida.
Other interventional cardiology in Winter Park
- Arthur LeeGainesville$1.8M
- Santhosh MathewsBradenton$1.4M
- Siddharth WayangankarJacksonville$1.2M
- Patrick CambierTrinity$901K
- Zahid AminOrlando$635K
- Rohit AminPensacola$560K
- Eduardo de MarchenaMiami$498K
- Dominick AngiolilloJacksonville$387K
- Miguel DiazHialeah$383K
- Douglas EbersoleLakeland$373K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.